HSV-1 infects 67 percent of people under age 50 worldwide. Primary genital HSV-1 cases now reach 50 to 60 percent in some US clinics. HSV-2 seroprevalence stands at 11.9 percent among US adults aged 14 to 49.
Key Takeaways
- Primary genital HSV-1 infections have increased to 50-60% in some US clinics
- Prodromal symptoms like tingling occur in 50% of recurrent genital herpes episodes
- Initial genital HSV-2 outbreak lasts 2-4 weeks with 80-90% experiencing systemic symptoms like fever
- HSV PCR detects shedding in 70-80% culture-positive lesions
- Type-specific HSV-2 IgG sensitivity 96%, specificity 97% (HerpeSelect)
- Viral culture sensitivity 50-70% for genital lesions, lower for oral
- Globally, approximately 3.7 billion people under the age of 50 (67%) are infected with HSV-1
- In the United States, 47.8% of people aged 14-49 have HSV-1
- HSV-2 seroprevalence among US adults aged 14-49 is 11.9%
- Transmission risk from male to female is 4% per year in discordant couples without condoms
- Asymptomatic viral shedding accounts for 70% of HSV-2 transmissions
- Condom use reduces HSV-2 transmission by 30-50%
- Acyclovir 400mg TID for 7-10 days heals 80% primary genital lesions in 5 days
- Valacyclovir 1g daily suppresses recurrences by 77%, shedding 50%
- Famciclovir 250mg TID episodic therapy shortens outbreaks by 1.8 days
HSV affects billions globally, and ongoing shedding drives frequent outbreaks, complications, and transmission.
Related reading
01 · Category
Clinical Features28 stats
01
Primary genital HSV-1 infections have increased to 50-60% in some US clinics
02
Prodromal symptoms like tingling occur in 50% of recurrent genital herpes episodes
03
Initial genital HSV-2 outbreak lasts 2-4 weeks with 80-90% experiencing systemic symptoms like fever
04
Oral HSV-1 lesions (cold sores) recur 4 times per year on average
05
Genital herpes lesions are painful vesicles/ulcers in 80% of first episodes
06
Aseptic meningitis complicates 36% of primary genital HSV-2 infections
07
Herpetic whitlow (finger infection) occurs in 10-20% of healthcare workers exposed to HSV
08
Neonatal herpes presents with skin/eye/mouth (SEM) disease in 45%, CNS in 30%, disseminated in 25%
09
Recurrent genital HSV episodes average 4-5 per year without therapy
10
HSV keratitis affects 300,000-500,000 cases annually worldwide
11
Erythema multiforme follows HSV reactivation in 75% of cases
12
Genital HSV-1 recurrences are fewer (0.5/year) vs HSV-2 (4/year)
13
Bell's palsy associated with HSV-1 in 70% of idiopathic cases via PCR
14
HSV encephalitis mortality is 70% without treatment, 40% with acyclovir
15
Pain from genital herpes lasts 7-10 days in primary episodes, 3-5 in recurrences
16
Extragenital lesions (buttocks/thighs) in 20-30% of genital herpes cases
17
HSV-2 increases HIV acquisition risk by 3-fold
18
Oral-labial HSV lesions heal in 7-10 days without scarring
19
In immunocompromised, HSV causes chronic ulcerative lesions in 80%
20
Prodrome duration is 48 hours before lesions in 60% genital cases
21
HSV proctitis symptoms include severe pain/tenesmus in 90% MSM cases
22
Neonatal HSV mortality is 60% for disseminated, 5% for SEM with treatment
23
Autonomic dysreflexia in sacral HSV radiculitis in 10% cases
24
HSV-associated esophagitis in 50% of AIDS patients with odynophagia
25
Recurrent corneal HSV in 27-45% after first episode
26
Genital herpes shedding occurs asymptomatically in 10-20% days for HSV-2
27
Urinary retention from sacral neuropathy in 15-20% primary genital HSV women
28
HSV-1 gingivostomatitis in children causes fever in 80%, dehydration risk 20%
Interpretation
Clinical Features Interpretation
While it may start as an inconvenient tingle, HSV reveals itself as a systemic saboteur, capable of igniting anything from annual cold sores and painful outbreaks to life-threatening encephalitis and a threefold invitation for HIV.
02 · Category
Diagnosis26 stats
01
HSV PCR detects shedding in 70-80% culture-positive lesions
02
Type-specific HSV-2 IgG sensitivity 96%, specificity 97% (HerpeSelect)
03
Viral culture sensitivity 50-70% for genital lesions, lower for oral
04
NAAT/PCR sensitivity 95-100% for HSV detection in lesions
05
Western blot gold standard for HSV-2 serology, specificity >99%
06
False-positive HSV-2 IgG in 50% low-index HerpeSelect results
07
Tzanck smear shows multinucleated giant cells in 60% vesicular lesions
08
HSV CSF PCR sensitivity 98% for encephalitis
09
Neonatal HSV diagnosis: surface cultures positive in 90% SEM disease
10
Biokit HSV-2 rapid test sensitivity 92%, specificity 98%
11
DFA immunofluorescence sensitivity 80-90% for lesion swabs
12
HSV-1/2 type-specific serology positive 3-6 weeks post-infection
13
Focus ELISA HSV-2 index <1.1 negative, 1.1-3.5 indeterminate
14
Brain biopsy needed in <5% HSV encephalitis for diagnosis pre-PCR
15
Point-of-care HSV-2 tests like Sure Check sensitivity 90.5%
16
IgM unreliable for acute HSV (false pos 30-50%)
17
Swab from vesicle base optimal for PCR/culture
18
HSV resistance genotyping via PCR in 5% acyclovir failures
19
Serology detects 70% HSV-2 infections missed clinically
20
Keratitis diagnosis: dendritic ulcers on fluorescein 95% specific
21
HSV load by qPCR >10^3 copies/mL predicts transmission risk
22
Cross-reactivity HSV-1 IgG with HSV-2 tests <5% modern assays
23
CSF pleocytosis in 90% HSV meningitis
24
Rapid antigen tests sensitivity <70%, not recommended
25
Confirmatory Western blot for equivocal EIA in 50% reclassify
26
HSV DNA in 75% corneal scrapings stromal keratitis
Interpretation
Diagnosis Interpretation
Navigating HSV diagnostics is a choose-your-own-adventure book where the gold standard is often in a different chapter, but a clever detective uses PCR's sharp eye, respects the Western blot's final verdict, and never trusts a rapid test with a good poker face.
03 · Category
Epidemiology30 stats
01
Globally, approximately 3.7 billion people under the age of 50 (67%) are infected with HSV-1
02
In the United States, 47.8% of people aged 14-49 have HSV-1
03
HSV-2 seroprevalence among US adults aged 14-49 is 11.9%
04
In sub-Saharan Africa, HSV-2 prevalence among adults is over 50% in many populations
05
Lifetime risk of acquiring HSV-2 for women is 1 in 5, compared to 1 in 10 for men
06
HSV-1 prevalence increases with age, reaching 80-90% in some developing countries
07
In Europe, HSV-1 seroprevalence in children under 10 is about 20-30%
08
HSV-2 infection rates are highest among African Americans at 34.6% in US
09
Globally, 491 million people aged 15-49 (13%) have HSV-2
10
Annual incidence of HSV-2 in the US is approximately 417,000 infections
11
HSV-1 causes 10% of genital herpes cases worldwide
12
In pregnant women, HSV-2 seroprevalence is 20-25% in the US
13
HSV-1 oral prevalence in US adolescents (14-19) is 28.1%
14
In India, HSV-2 seroprevalence is 10-15% among antenatal women
15
HSV-2 prevalence among men who have sex with men is 20-25%
16
Global HSV-1 incidence in 2016 was 25.6 million new cases among 15-49 year olds
17
In Latin America, HSV-2 prevalence averages 15% in general population
18
HSV-1 seroprevalence in US adults 40-49 is 57.8%
19
Among commercial sex workers, HSV-2 prevalence exceeds 60% in many regions
20
HSV-2 incidence rate is 5.2 per 1000 person-years in discordant couples
21
In Australia, HSV-1 prevalence is 58% in adults
22
HSV-2 seroprevalence in UK general population is 9.5%
23
In China, HSV-2 prevalence among pregnant women is 7.9%
24
HSV-1 causes 90% of oral herpes but increasing genital cases at 50% in some young populations
25
Global burden: HSV-2 causes 202 million new genital ulcer episodes yearly
26
In Brazil, HSV-2 seroprevalence is 15.7% among women
27
HSV-1 seropositivity in US children 0-12 years is 20.1%
28
Among HIV-positive individuals, HSV-2 prevalence is 60-90%
29
Annual global HSV-2 new infections: 26 million in women, 23 million in men aged 15-49
30
In South Africa, HSV-2 prevalence in adults 20-49 is 56%
Interpretation
Epidemiology Interpretation
While two-thirds of humanity quietly hosts HSV-1 like an uninvited but permanent roommate, its more intimate cousin HSV-2 operates with brutal demographic precision, disproportionately claiming women, the young, and entire regions with a statistical indifference that is both globally staggering and personally devastating.
More related reading
04 · Category
Transmission29 stats
01
Transmission risk from male to female is 4% per year in discordant couples without condoms
02
Asymptomatic viral shedding accounts for 70% of HSV-2 transmissions
03
Condom use reduces HSV-2 transmission by 30-50%
04
HSV-2 transmission probability per act: 0.05% from male to female, 0.01% female to male
05
Oral-genital transmission of HSV-1 causes 30-50% new genital herpes in young adults
06
Daily valacyclovir reduces transmission by 48% in discordant couples
07
HSV-2 shedding rate: 15-30% of days in first year post-infection
08
Neonates acquire HSV intrapartum in 85% cases, 5% postnatal, 10% intrauterine
09
Circumcision reduces HSV-2 acquisition by 28-34%
10
HSV-1 oral shedding 20% of days in seropositive persons
11
Risk doubles with genital ulcers present during intercourse
12
Serodiscordant couples: annual transmission 5-10% without intervention
13
Antiviral suppressive therapy cuts shedding by 95%
14
HSV-2 prevalent in 50% of HIV-discordant couples in Africa
15
Hand-genital contact transmits HSV rarely (<1%)
16
C-section reduces neonatal transmission from 30-50% to <5% in active lesions
17
HSV shedding peaks at 20-50% days in first 6 months, declines to 10-15% long-term
18
Female-to-male transmission 10% lower than male-to-female due to anatomy
19
Spermicides/nonoxynol-9 ineffective against HSV transmission
20
HSV-1 genital acquisition from oral sex: 1-2% per year exposure
21
Breakthrough shedding on suppressive therapy: 3-5% days for HSV-2
22
Zosteriform HSV pattern from autoinoculation in 5% cases
23
HSV-2 increases per-act HIV transmission 2-3 fold
24
Abstinence during prodrome reduces transmission by 90%
25
Non-penetrative sex transmission risk <1% per act
26
Vaginal drying practices increase HSV-2 acquisition 1.5-fold in Africa
27
HSV IgG positivity predicts 80% transmission risk concordance
28
Fomites (towels) transmit HSV <0.1% effectively
29
Serosorting reduces HSV-2 transmission 50% in MSM
Interpretation
Transmission Interpretation
Nature's irritating design is that herpes mostly spreads when you wouldn't suspect it, through asymptomatic shedding, but the math thankfully shows that consistent condoms, daily antivirals, and avoiding sex during outbreaks can seriously stack the odds in your favor.
05 · Category
Treatment24 stats
01
Acyclovir 400mg TID for 7-10 days heals 80% primary genital lesions in 5 days
02
Valacyclovir 1g daily suppresses recurrences by 77%, shedding 50%
03
Famciclovir 250mg TID episodic therapy shortens outbreaks by 1.8 days
04
Acyclovir IV 10mg/kg q8h for neonatal HSV, survival 85% SEM
05
Foscarnet for acyclovir-resistant HSV (5% immunocompromised)
06
Suppressive therapy reduces recurrences from 3.8 to 0.7/year
07
Topical acyclovir 3x daily heals cold sores 0.5-1 day faster
08
C-section indicated if membranes ruptured >4h with active lesions
09
Acyclovir prophylaxis last 4 weeks pregnancy reduces lesions 75%
10
Laser therapy for HSV keratitis reduces recurrences 50% in meta-analysis
11
Long-term suppressive valacyclovir safe >5 years, resistance <0.5%
12
Episodic famciclovir 1g BID x1 day aborts 25% prodromal episodes
13
Cidofovir topical for resistant mucocutaneous HSV 80% response
14
Acyclovir 800mg 5x/day for encephalitis, reduces mortality to 19%
15
Prophylaxis post-bone marrow transplant: acyclovir reduces HSV 80%
16
Single-dose famciclovir 1500mg shortens lesion time 1.5 days
17
Imiquimod topical increases healing but more local reactions
18
Helium-neon laser aborts cold sores in 70% if early
19
Acyclovir + steroids controversial for Bell's palsy, 10% better recovery
20
Chronic suppressive therapy cost-effective if >6 recurrences/year
21
Tenofovir gel reduces HSV-2 acquisition 51% in women
22
Docosanol 10% cream shortens cold sores 12 hours
23
High-dose acyclovir (30mg/kg/day) for visceral HSV in immunocompromised
24
Vaccine trials: Simplirix 73% efficacy vs HSV-2 disease
Interpretation
Treatment Interpretation
While the pharmacy of HSV interventions offers everything from the elegantly effective (valacyclovir cutting recurrences by 77%) to the heroically high-stakes (IV acyclovir saving neonatal lives), the unifying theme is that whether you're preventing, suppressing, or fighting this tenacious virus, modern medicine has a reasonably clever, statistically-backed countermove for nearly every front it attacks.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Nathan Caldwell. (2026, February 13). Hsv Statistics. Gitnux. https://gitnux.org/hsv-statistics
MLA
Nathan Caldwell. "Hsv Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hsv-statistics.
Chicago
Nathan Caldwell. 2026. "Hsv Statistics." Gitnux. https://gitnux.org/hsv-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level